{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T11:39:33Z","timestamp":1792582773245,"version":"4.5.0"},"reference-count":56,"publisher":"Informa UK Limited","issue":"1","license":[{"start":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T00:00:00Z","timestamp":1792540800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T00:00:00Z","timestamp":1792540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/doi.org\/10.1080\/policies-text-data-mining"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Journal of Medical Economics"],"published-print":{"date-parts":[[2026,12,31]]},"DOI":"10.1080\/13696998.2026.2746279","type":"journal-article","created":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T10:45:03Z","timestamp":1792579503000},"page":"2572-2586","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":0,"title":["Healthcare utilization and costs associated with dextromethorphan-bupropion versus selected other branded treatments for major depressive disorder: a US real-world study"],"prefix":"10.1080","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6098-9266","authenticated-orcid":false,"given":"Leslie","family":"Citrome","sequence":"first","affiliation":[{"name":"New York Medical College","place":["Valhalla, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-2266-8420","authenticated-orcid":false,"given":"Yang","family":"Zhao","sequence":"additional","affiliation":[{"name":"Axsome Therapeutics, Inc","place":["New York, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Courtney","family":"Zeni","sequence":"additional","affiliation":[{"name":"Axsome Therapeutics, Inc","place":["New York, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3127-4365","authenticated-orcid":false,"given":"Nicole","family":"Princic","sequence":"additional","affiliation":[{"name":"Merative","place":["Ann Arbor, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0737-389X","authenticated-orcid":false,"given":"Megan","family":"Richards","sequence":"additional","affiliation":[{"name":"Merative","place":["Ann Arbor, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-5987-6806","authenticated-orcid":false,"given":"Shawn P.","family":"Alter","sequence":"additional","affiliation":[{"name":"Axsome Therapeutics, Inc","place":["New York, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5800-0378","authenticated-orcid":false,"given":"Andrew J.","family":"Cutler","sequence":"additional","affiliation":[{"name":"SUNY Upstate Medical University","place":["Syracuse, USA"]},{"name":"Neuroscience Education Institute","place":["Lakewood Ranch, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2026,10,21]]},"reference":[{"key":"e_1_3_5_2_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2017.4602"},{"key":"e_1_3_5_3_1","unstructured":"World Health Organization. Depressive disorder (depression). 2026. Available from: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/depression"},{"key":"e_1_3_5_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(26)00519-2"},{"key":"e_1_3_5_5_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12888-022-04165-x"},{"key":"e_1_3_5_6_1","doi-asserted-by":"publisher","DOI":"10.1177\/07067437241245384"},{"key":"e_1_3_5_7_1","unstructured":"US Department of Veterans Affairs\/Department of Defense. VA\/DOD clinical practice guideline for the management of major depressive disorder. 2022. Available from: https:\/\/www.healthquality.va.gov\/HEALTHQUALITY\/guidelines\/MH\/mdd\/VADODMDDCPGFinal508.pdf"},{"key":"e_1_3_5_8_1","doi-asserted-by":"publisher","DOI":"10.1080\/13651501.2019.1699575"},{"key":"e_1_3_5_9_1","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2021.813130"},{"key":"e_1_3_5_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-023-02622-x"},{"key":"e_1_3_5_11_1","unstructured":"American Psychological Association. Clinical practice guideline for the treatment of depression across three age cohorts. 2019. Available from: https:\/\/www.apa.org\/depression-guideline\/guideline.pdf"},{"issue":"2","key":"e_1_3_5_12_1","doi-asserted-by":"crossref","first-page":"196","DOI":"10.7326\/M22-1845","article-title":"Nonpharmacologic and pharmacologic treatments of adult patients with major depressive disorder: a systematic review and network meta-analysis for a clinical guideline by the American College of Physicians","volume":"176","author":"Garltehner G","year":"2023","unstructured":"Garltehner G, Dobrescu A, Chapman A, et al. Nonpharmacologic and pharmacologic treatments of adult patients with major depressive disorder: a systematic review and network meta-analysis for a clinical guideline by the American College of Physicians. Ann Intern Med. 2023;176(2):196\u2013211.","journal-title":"Ann Intern Med"},{"issue":"2","key":"e_1_3_5_13_1","first-page":"173","article-title":"Pharmacologic treatment of depression","volume":"107","author":"Kovich H","year":"2023","unstructured":"Kovich H, Kim W, Quaste AM. Pharmacologic treatment of depression. Am Fam Physician. 2023;107(2):173\u2013181.","journal-title":"Am Fam Physician"},{"key":"e_1_3_5_14_1","doi-asserted-by":"publisher","DOI":"10.7326\/M22-2056"},{"key":"e_1_3_5_15_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12888-025-07141-3"},{"key":"e_1_3_5_16_1","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.2006.163.11.1905"},{"key":"e_1_3_5_17_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.163.1.28"},{"key":"e_1_3_5_18_1","doi-asserted-by":"publisher","DOI":"10.1080\/00325481.2023.2189868"},{"key":"e_1_3_5_19_1","unstructured":"AUVELITY [Full Prescribing Information]. New York (NY): Axsome Therapeutics Inc. https:\/\/www.axsome.com\/wp-content\/uploads\/2024\/11\/auvelity-prescribing-information.pdf"},{"key":"e_1_3_5_20_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.21m14345"},{"key":"e_1_3_5_21_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.21080800"},{"key":"e_1_3_5_22_1","volume-title":"Poster session presented at: ASCP 2021 Annual Meeting","author":"O\u2019Gorman C","year":"2021","unstructured":"O\u2019Gorman C, Jones A, Tabuteau H. Sustained efficacy with long-term treatment with AXS-05: results from the COMET phase 3 trial, a long-term, open-label study evaluating the efficacy and safety of AXS-05 for the treatment of MDD. Poster session presented at: ASCP 2021 Annual Meeting; 2021 Jun 1\u20134. Virtual meeting."},{"key":"e_1_3_5_23_1","doi-asserted-by":"publisher","DOI":"10.9758\/cpn.23.1081"},{"key":"e_1_3_5_24_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-023-01032-5"},{"key":"e_1_3_5_25_1","volume-title":"Poster session presented at: NNDC 2025 Annual Conference","author":"Iosifescu DV","year":"2025","unstructured":"Iosifescu DV, Streicher C, Tabuteau H, et al. Efficacy, tolerability, and safety of AXS-05, a novel oral antidepressant: data from 3 clinical trials. Poster session presented at: NNDC 2025 Annual Conference; 2025 September 10\u201311, Cincinnati, OH."},{"key":"e_1_3_5_26_1","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2024.2382641"},{"key":"e_1_3_5_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/wps.21120"},{"key":"e_1_3_5_28_1","unstructured":"REXULTI [Full Prescribing Information]. Princeton (NJ): Otsuka America Pharmaceutical Inc. https:\/\/www.otsuka-us.com\/media\/static\/Rexulti-PI.pdf"},{"key":"e_1_3_5_29_1","unstructured":"VRAYLAR [Full Prescribing Information]. North Chicago (IL): Abbvie Inc. https:\/\/www.rxabbvie.com\/pdf\/vraylar_pi.pdf"},{"key":"e_1_3_5_30_1","unstructured":"SPRAVATO [Full Prescribing Information]. Titusville (NJ): Janssen Pharmaceuticals Inc. https:\/\/www.jnjlabels.com\/package-insert\/product-monograph\/prescribing-information\/SPRAVATO-pi.pdf"},{"key":"e_1_3_5_31_1","unstructured":"CAPLYTA [Full Prescribing Information]. Titusville (NJ): Intra-Cellular Therapies Inc. (Janssen Pharmaceuticals Inc.). https:\/\/www.jnjlabels.com\/package-insert\/product-monograph\/prescribing-information\/CAPLYTA-pi.pdf"},{"key":"e_1_3_5_32_1","doi-asserted-by":"publisher","DOI":"10.1097\/00001648-200009000-00011"},{"key":"e_1_3_5_33_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2023.0777"},{"key":"e_1_3_5_34_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.21r14328"},{"key":"e_1_3_5_35_1","doi-asserted-by":"publisher","DOI":"10.4088\/PCC.22r03330"},{"key":"e_1_3_5_36_1","doi-asserted-by":"publisher","DOI":"10.1002\/wps.21110"},{"key":"e_1_3_5_37_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.289.23.3095"},{"key":"e_1_3_5_38_1","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2021.27.2.223"},{"key":"e_1_3_5_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2015.12.029"},{"key":"e_1_3_5_40_1","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2020.1776297"},{"key":"e_1_3_5_41_1","unstructured":"American Psychiatric Association. Practice guidelines for the treatment of patients with major depressive disorder. 2010. Available from: https:\/\/psychiatryonline.org\/pb\/assets\/raw\/sitewide\/practice_guidelines\/guidelines\/mdd.pdf"},{"key":"e_1_3_5_42_1","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2023.29.6.614"},{"key":"e_1_3_5_43_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-021-01029-2"},{"key":"e_1_3_5_44_1","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2021.1911975"},{"key":"e_1_3_5_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2022.09.005"},{"key":"e_1_3_5_46_1","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2022.28.11-a.s1"},{"issue":"5","key":"e_1_3_5_47_1","first-page":"370","article-title":"Cost burden of treatment resistance in patients with depression","volume":"16","author":"Gibson TB","year":"2010","unstructured":"Gibson TB, Jing Y, Smith Carls G, et al. Cost burden of treatment resistance in patients with depression. Am J Manag Care. 2010;16(5):370\u2013377.","journal-title":"Am J Manag Care"},{"key":"e_1_3_5_48_1","doi-asserted-by":"publisher","DOI":"10.2165\/00019053-200927060-00006"},{"issue":"9","key":"e_1_3_5_49_1","first-page":"978","article-title":"Relationship between social determinants of health and hospitalizations and costs in patients with major depressive disorder","volume":"30","author":"Tiegland C","year":"2024","unstructured":"Tiegland C, Mohammadi I, Agatep BC, et al. Relationship between social determinants of health and hospitalizations and costs in patients with major depressive disorder. J Manag Care Spec Pharm. 2024;30(9):978\u2013990.","journal-title":"J Manag Care Spec Pharm"},{"key":"e_1_3_5_50_1","unstructured":"J&J prices ketamine-like depression treatment at $590-$885 for two doses. Reuters [Internet]. 2019 Mar 6. Available from: https:\/\/www.reuters.com\/article\/business\/jj-prices-ketamine-like-depression-treatment-at-590-885-for-two-doses-idUSKCN1QN2C5\/"},{"key":"e_1_3_5_51_1","unstructured":"Disclosure of information for prescribers of prescription drugs within Colorado (C.R.S.A. \u00a7 12-280-308) AUVELITY (dextromethorphan HBr and bupropion HCl) extended-release tablets. 2026. Available from: https:\/\/www.axsome.com\/wp-content\/uploads\/2024\/11\/auvelity-colorado.pdf"},{"key":"e_1_3_5_52_1","unstructured":"Information for Vermont prescribers of prescription drugs AUVELITY (dextromethorphan HBr and bupropion HCl) extended release tablets. 2026. Available from: https:\/\/www.axsome.com\/wp-content\/uploads\/2024\/11\/auvelity-vermont-long.pdf"},{"key":"e_1_3_5_53_1","unstructured":"VRAYLAR (cariprazine) Cost & savings. 2026. Available from: https:\/\/www.vraylar.com\/cost-and-savings"},{"key":"e_1_3_5_54_1","unstructured":"REXULTI (brexpiprazole) Savings & cost. 2026. Available from: https:\/\/www.rexulti.com\/savings-cost"},{"key":"e_1_3_5_55_1","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2023.2208993"},{"key":"e_1_3_5_56_1","doi-asserted-by":"publisher","DOI":"10.3390\/jpm15040161"},{"key":"e_1_3_5_57_1","doi-asserted-by":"crossref","first-page":"116655","DOI":"10.1016\/j.psychres.2025.116655","article-title":"Effectiveness of repeated esketamine nasal spray administration on anhedonic symptoms in treatment-resistant bipolar and unipolar depression: a secondary analysis from the REAL-ESK study group","volume":"352","author":"d\u2019Andrea G","year":"2025","unstructured":"d\u2019Andrea G, Cavallotto C, Pettorruso M, et al. Effectiveness of repeated esketamine nasal spray administration on anhedonic symptoms in treatment-resistant bipolar and unipolar depression: a secondary analysis from the REAL-ESK study group. Psychiatry Res. 2025;352:116655.","journal-title":"Psychiatry Res"}],"container-title":["Journal of Medical Economics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13696998.2026.2746279","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/full-xml\/10.1080\/13696998.2026.2746279","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13696998.2026.2746279","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T10:45:07Z","timestamp":1792579507000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/13696998.2026.2746279"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,21]]},"references-count":56,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12,31]]}},"alternative-id":["10.1080\/13696998.2026.2746279"],"URL":"https:\/\/doi.org\/10.1080\/13696998.2026.2746279","relation":{},"ISSN":["1369-6998","1941-837X"],"issn-type":[{"value":"1369-6998","type":"print"},{"value":"1941-837X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,21]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijme20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijme20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2026-06-30","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-10-05","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-10-06","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-10-21","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}